The antitumor immune activation effects of RT suggest that low-dose RT combined with ICIs could effectively control tumor metastasis by mobilizing innate and adaptive immunity, downregulating immunosuppressive factors such as Transforming Growth Factor-βeta (TGF-β), and partially reversing and delaying immune resistance.28 This evidence concerns the gene TGFB1 and neoplasm.